Viewing StudyNCT05346354



Ignite Creation Date: 2024-05-06 @ 5:33 PM
Last Modification Date: 2024-10-26 @ 2:31 PM
Study NCT ID: NCT05346354
Status: RECRUITING
Last Update Posted: 2024-06-04
First Post: 2022-04-20

Brief Title: Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Sponsor: Alexion Pharmaceuticals Inc
Organization: Alexion Pharmaceuticals Inc

Conditions & Keywords Data

Conditions:
Name
Neuromyelitis Optica Spectrum Disorder
Keywords:
Name View
NMOSD View
Neuromyelitis Optica Spectrum Disorder View
Ravulizumab View
ALXN1210 View
CNS Autoimmune Disorders View
NMO View